ReviewCancer medicine2026
Effects of Tumor Microenvironment on Lung Cancer Stem Cells: Bidirectional Regulatory Mechanisms.
Review in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lung cancer, with a high mortality rate, poses challenges in treatment due to its invasiveness and heterogeneity. Lung cancer stem cells (LCSCs) are considered key contributors to recurrence and metastasis because of their self-renewal, pluripotency, and drug resistance. The tumor microenvironment (TME) is intricately intertwined with LCSCs, where cellular factors, hypoxic conditions, and extracellular matrix components within the TME modulate LCSCs' properties through various signaling pathways. This review analyzes the interaction between the TME and LCSCs, elucidates their regulatory mechanisms, and explores potential therapeutic strategies based on these mechanisms, including immunotherapy, anti-angiogenesis therapy, and targeting CAFs and stromal metabolism. We believe that a deeper understanding of the interaction between the TME and LCSCs is crucial for the development of novel therapeutic approaches and may offer more effective treatment options for lung cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.